SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (379)5/3/2002 12:08:50 PM
From: nigel bates  Read Replies (1) of 1022
 
An attempt at a timeline for MEDX (selected highlights only <g>).
What strikes me is that they have surprisingly little to show for some pretty heavyweight alliances which date back several years. I have left out an awful lot of deals, many of which are with smaller companies.

Pre 1997
Leukosite, Centeon (later acquired by Aventis ?)
1997
Kirin (TC Mouse deal), Centocor (deal to generate mAbs to 4 antigens)
1998
Feb Schering (to generate mAb to a proprietory antigen)
June BMY (multiple antigen deal)
Nov Novartis (10yr Global unlimited technology license)
Nov Centeon (milestone on MDX-33 P1 results for ITP)
1999
Jan IMNX
Jan Centocor (milestone on mAb to IL-12)
Feb LKST (expanded agreement)
May Schering (expanded agreement)
Sept AMGN
Nov Novartis (technology acess fee)
2000
Jan Kirin (strategic alliance)
May J&J/Centocor (technology deal -unlimited no. of mAbs)
June MEDI
June Biosite (Transphage tech. deal)
Sept OGSI
Nov Lilly (MEDX to generate mAbs)
Dec 'UltimAb' tech. announced
Dec Aventis (announce +ve P11 results for MDX-33 in ITP)
2001
Jan Lilly (Transphage tech. deal)
Feb J&J/Centocor (IND on first mAb developed thru MEDX technology)
Mar Schering (UltimAb collaboration)
June HGSI
Oct INCY

Excepting the IDM and Genmab antibodies (I have deliberately left them off the above list), MEDX has only two mAbs in the clinic partnered with/outlicenced to independent companies - MDX-33 for ITP, which results from a collaboration dating back before 1997, and is apparently still in P11, and a mAb resulting from the Centocor alliance in PI trials for an "undisclosed" anti-inflammatory indication.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News